scholarly journals Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG)

2018 ◽  
Vol 137 (2) ◽  
pp. 313-319 ◽  
Author(s):  
Lei Qin ◽  
Angie Li ◽  
Jinrong Qu ◽  
Katherine Reinshagen ◽  
Xiang Li ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Grade Glioma ◽  
High Grade ◽  
Improve Correlation

OS03.4.A Irradiation of the subventricular and subgranular zone and overall survival in high-grade glioma patients

2021 ◽  
Vol 23 (Supplement_2) ◽  
pp. ii6-ii6
Author(s):  
D Bruil ◽  
S David ◽  
S Nagtegaal ◽  
J Verhoeff
Keyword(s):  
Overall Survival ◽  
Confidence Interval ◽  
High Grade Glioma ◽  
Radiotherapy Planning ◽  
Intracranial Volume ◽  
High Grade ◽  
Subgranular Zone ◽  
Median Dose ◽  
Repair Capacity ◽  
The Mean

Abstract BACKGROUND Previous research has shown that neural stem cells (NSCs) in the subventricular zone (SVZ) may support the growth of glioma by recruiting new cells to the tumor. NSCs are located in the SVZ as well as in the subgranular zone (SGZ) of the hippocampus, the two neurogenic niches of the brain. This might indicate that irradiation of the SVZ and SGZ, and thereby damaging NSCs, reduces tumor growth and improves overall survival (OS). However, irradiation may also inhibit the repair capacity of healthy brain tissue by these neurogenic niches. Therefore, we investigated the effects of SVZ and SGZ irradiation dose on OS, in a cohort of high-grade glioma patients. MATERIAL AND METHODS We have retrospectively selected 221 patients (2014–2020) with WHO grade III and IV gliomas that underwent radiotherapy. Next to clinical baseline characteristics, T1 weighted MRI- and CT-images were collected. The SVZ and SGZ regions on the individual T1 images were delineated via non-linear registration of brain atlases. SVZ labels were created in 0.5mm isotropic MNI T1 and T2 templates, while SGZ atlas labels were available via the Hippocampus and Subfields CoBrA atlas. Next, the mean dose from the acquired SVZ and SGZ labels were extracted. The relationship between SVZ doses, SGZ doses and OS were examined using the Cox proportional hazards model and the Kaplan-Meier method (using the Log Rank test for significance). RESULTS For the mean dose in the SVZ, the hazard ratio (HR) was 1.024 per Gy (P = 0.002, [95% confidence interval, 1.009–1.040]) and the mean SGZ dose had a HR of 1.021 per Gy (P< 0.001, [95% confidence interval, 1.012–1.031]). These results were then corrected for the following covariates: sex, age, total intracranial volume and extent of surgery. This resulted in a HR of 1.031 per Gy (P = 0,001, [95% confidence interval, 1.014–1.050]) for the mean SVZ dose, and a HR of 1.025 per Gy (P< 0.001, [95% confidence interval, 1.015–1.036]) for the mean SGZ dose. Patients whose SVZ received greater than the median SVZ dose (= 31.3 Gy) showed a significant decrease in OS compared to patients who received less than the median dose (10.7 months vs 13.5 months median OS, P = 0.001). Patients whose SGZ received greater than the median SGZ dose (= 31.9) showed a significant decrease in OS compared to patients who received less than the median dose (10.7 months vs 15.1 months median OS, P< 0.001). CONCLUSION Here, we present a large cohort of high-grade glioma patients, in which we show a statistically significant decrease in overall survival with increasing radiation dose on the SGZ and SVZ. This correlation suggests that both neurogenic niches might need to be spared during radiotherapy treatment to improve overall survival even in high-grade glioma patients. Modern radiotherapy planning and delivery options are available to implement this.

scholarly journals SURG-24. OVERALL SURVIVAL IN A SYNGENEIC RODENT ORTHOTOPIC HIGH-GRADE GLIOMA MODEL IS SIGNIFICANTLY PROLONGED BY NEUROSURGICAL DELIVERY OF PLGA/PEG INTERSTITIAL CHEMOTHERAPY

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi240-vi240
Author(s):  
Stuart Smith ◽  
Toby Gould ◽  
Betty Tyler ◽  
Alison Ritchie ◽  
Gareth Veal ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Grade Glioma ◽  
High Grade ◽  
Interstitial Chemotherapy ◽  
Glioma Model

Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients

2016 ◽  
Vol 85 (3) ◽  
pp. 657-664 ◽  
Author(s):  
Jinrong Qu ◽  
Lei Qin ◽  
Suchun Cheng ◽  
Katherine Leung ◽  
Xiang Li ◽  
...  
Keyword(s):  
Overall Survival ◽  
Resection Margin ◽  
High Grade Glioma ◽  
High Grade

scholarly journals Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: A population-based analysis

2019 ◽  
Author(s):  
Yun Sun ◽  
Zhi-yong Xiong ◽  
Peng-fei Yan ◽  
Liang-lei Jiang ◽  
Chuan-sheng Nie ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Survival Data ◽  
Age Groups ◽  
High Grade Glioma ◽  
Population Based ◽  
High Grade ◽  
Treatment Protocols ◽  
Cox Models ◽  
Cause Specific Survival

We evaluated characteristics and different prognostic factors for survival in age-stratified high-grade glioma in a US cohort. Eligible patients were identified in the Surveillance, Epidemiology, and End Results (SEER) registries and stratified into 3 age groups: 20-39 years old (1,043 patients), 40-59 years old (4,503 patients), and >60 years old (5,045 patients). Overall and cancer-related survival data were obtained. Cox models were built to analyze the outcomes and risk factors. It showed that race was a prognostic factor for survival in patients 40 to 59 years old and in patients ≥60 years old. Partial resection was associated with lower overall survival and cause-specific survival in all age groups (overall survival: 20-39 yr: HR=6.41; 40-59 yr: HR=4.84; >60 yr: HR=5.06; cause-specific survival: 20-39 yr: HR=5.87; 40-59 yr: HR=4.01; >60 yr: HR=3.36). The study highlights that, while some prognostic factors are universal, others are age-dependent. The effectiveness of treatment approaches differs for patients in different age groups. Results of this study may help to develop personalized treatment protocols for glioma patients of different ages.

Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience

2020 ◽  
pp. 107815522092068
Author(s):  
Ozkan Alan ◽  
Tugba Akin Telli ◽  
Tugba Basoglu Tuylu ◽  
Rukiye Arikan ◽  
Nazım Can Demircan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Systemic Treatment ◽  
Progression Free Survival ◽  
High Grade Glioma ◽  
Idh1 Mutation ◽  
High Grade ◽  
Free Survival ◽  
Median Progression Free Survival ◽  
Ecog Ps

Purpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17–77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1–68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.

scholarly journals Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation

2018 ◽  
Vol 10 ◽  
pp. 47-52 ◽  
Author(s):  
Antoine Schernberg ◽  
Alexandre Nivet ◽  
Frédéric Dhermain ◽  
Samy Ammari ◽  
Alexandre Escande ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Grade Glioma ◽  
High Grade ◽  
Newly Diagnosed

scholarly journals Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival

2008 ◽  
Vol 26 (20) ◽  
pp. 3387-3394 ◽  
Author(s):  
Daniel A. Hamstra ◽  
Craig J. Galbán ◽  
Charles R. Meyer ◽  
Timothy D. Johnson ◽  
Pia C. Sundgren ◽  
...  
Keyword(s):  
Overall Survival ◽  
Median Survival ◽  
Patient Survival ◽  
Characteristic Curve ◽  
High Grade Glioma ◽  
Cox Proportional Hazards ◽  
Response To Therapy ◽  
Imaging Biomarker ◽  
High Grade ◽  
Diffusion Map

PurposeAssessment of radiologic response (RR) for brain tumors utilizes the Macdonald criteria 8 to 10 weeks from the start of treatment. Diffusion magnetic resonance imaging (MRI) using a functional diffusion map (fDM) may provide an earlier measure to predict patient survival.Patients and MethodsSixty patients with high-grade glioma were enrolled onto a study of intratreatment MRI at 1, 3, and 10 weeks. Receiver operating characteristic curve analysis was used to evaluate imaging parameters as a function of patient survival at 1 year. Both log-rank and Cox proportional hazards models were utilized to assess overall survival.ResultsGreater increases in diffusion in response to therapy over time were observed in those patients alive at 1 year compared with those who died as a result of disease. The volume of tumor with increased diffusion by fDM at 3 weeks was the strongest predictor of patient survival at 1 year, with larger fDM predicting longer median survival (52.6 v 10.9 months; log-rank, P < .003; hazard ratio [HR] = 2.7; 95% CI, 1.5 to 5.9). Radiologic response at 10 weeks had similar prognostic value (median survival, 31.6 v 10.9 months; log-rank P < .0007; HR = 2.9; 95% CI, 1.7 to 7.2). Radiologic response and fDM differed in 25% of cases. A composite index of response including fDM and RR provided a robust predictor of patient survival and may identify patients in whom RR does not correlate with clinical outcome.ConclusionCompared with conventional neuroimaging, fDM provided an earlier assessment of equal predictive value, and the combination of fDM and RR provided a more accurate prediction of patient survival than either metric alone.

Sign in / Sign up

Export Citation Format

Share Document